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Background
For people living with HIV and AIDS
(PLHIV), treatment with antiretroviral ther-
apy (ART) can result in viral suppression,
prolonged life expectancy, and reduced HIV
transmission [1–3]. To realize these benefits,
PLHIV require regular access to medica-
tions and supportive services. Within con-
flict-affected settings, there are unique chal-
lenges to providing, accessing, and adhering
to ART [4,5]. An estimated 1.5 billion
people live in countries impacted by violent
conflict and 45.2 million are forcibly dis-
placed as a result of persecution, conflict,
violence, and/or human rights violations
[6,7]. In 2006, 1.8 million PLHIV were
affected by conflict, disaster, or displacement.
Half of countries (7/15) with the largest
number of PLHIV were affected by a major
conflict between 2002 and 2006 [8]. Con-
flict-affected persons reside in areas of recent
or active conflict, or in a post-conflict camp,
urban, or rural setting, and may be accorded
an official status depending on their situation
[9,10]. Refugee status is available to individ-
uals with ‘‘a well-founded fear of being
persecuted for reasons of race, religion,
nationality, membership of a particular
social group or political opinion, is outside
the country of his/her nationality and is
unable or unwilling (owing to such fear) to
avail him/herself of the protection of that
country’’ [11]. Internally displaced persons
(IDPs) are citizens who have ‘‘been forced or
obliged to flee or to leave their homes or
places of habitual residence, in particular as
a result of or in order to avoid the effects of
armed conflict, situations of generalized
violence, violations of human rights or
natural or human-made disasters, and who
have not crossed an internationally recog-
nized State border’’ [12]. A protracted
refugee situation occurs when .25,000
refugees of the same nationality have been
in exile for$5 years. At the end of 2012, 6.4
million refugees, or 61% of the global total
of 10.5 million, lived in a protracted situation
[7]. In the post-emergency phase of forced
displacement, refugees and IDPs live in
relatively ‘‘stable’’ settings, meaning that
exceptional measures are no longer required
to remove threats to life or well-being [13].
Here, we synthesize norms of practice with
evidence on the impact of ART programs in
stable settings, including our own experienc-
es delivering and evaluating ART as part of
the United Nations High Commissioner for
Refugees (UNHCR) mandate. We then
propose operational recommendations for
improving HIV treatment outcomes among
refugees and IDPs in stable settings. Moral,
legal, and public health principles, in
combination with recent evidence, provide
a clear rationale for sustainable treatment
provision and adequate support for refugees
and IDPs.
Equity and Sustainability
Debates over the merits of providing
ART to refugees and IDPs have echoed
earlier discussions on treatment scale-up
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Summary Points
N Available evidence suggests that refugees and internally displaced persons
(IDPs) in stable settings can sustain high levels of adherence and viral
suppression.
N Moral, legal, and public health principles and recent evidence strongly suggest
that refugees and IDPs should have equitable access to HIV treatment and
support.
N Exclusion of refugees and IDPs from HIV National Strategic Plans suggests that
they may not be included in future national funding proposals to major donors.
N Levels of viral suppression among refugees and nationals documented in a
stable refugee camp suggest that some settings require more intensive support
for all population groups.
N Detailed recommendations are provided for refugees and IDPs accessing
antiretroviral therapy in stable settings.
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in resource-constrained settings [14].
Four main arguments support the pro-
vision of ART to these groups: (1) the
evidence for clinical benefit, reduced
transmission, and cost-effectiveness sup-
ports the scaling-up of treatment to all
in need [15,16]; (2) where scarcity
exists, principles of fairness should be
applied uniformly to allocation of treat-
ment [17,18]; (3) the right to health,
including the principle of access to
essential medicines, clearly articulates a
rationale for providing access to life-
saving interventions for PLHIV [19–
21]; and (4) the Convention Relating to
the Status of Refugees enshrines a
principle of equity whereby hosting
countries should provide refugees with
a similar standard of medical care to the
standard that is routinely available to
host nationals [11,12].
In practice, however, countries do not
uniformly provide access to ART within
their borders [22], and international
assistance can be slow in reaching these
groups. Compared with unaffected coun-
tries, conflict-affected countries received
less than half of the funds provided
through overseas development assistance
(ODA) for reproductive health services in
the period 2006–2008 [23]. Funding
cycles are also temporary. Funding pro-
vided for refugees and local populations
by the World Bank through the Great
Lakes Initiative on AIDS for refugees and
surrounding host populations recently
ended, leading to a resource gap. Given
budget pressures, national governments
may give preferential treatment to na-
tionals and/or non-minorities. Funds
provided by the major donors such as
Global Fund to Fight AIDS, Tuberculosis
and Malaria (Global Fund), and the
President’s Emergency Plan for AIDS
Relief (PEPFAR) are less likely to find
groups who are excluded from national
funding proposals, an omission that is
more likely to occur when such margin-
alized groups are also excluded from HIV
National Strategic Plans (NSPs). Of NSPs
issued in the ten year period from 1998 to
2008 by African countries, only 52% and
43% mentioned refugees and IDPs,
respectively [24,25].
Evidence for Action
Evidence of effectiveness is needed to
support arguments for scaling-up treatment
and support. Findings from studies conducted
among refugees and IDPs showed that 87%–
99.5% of clients studied had achieved$95%
adherence and positive treatment outcomes,
as measured by survival and CD4 gains [26].
However, outside of high-income settings,
very few published studies have used virologic
outcomes to assess program performance.
One study that compared citizens with
‘‘foreigners’’ who relocated to Johannesburg
found higher levels of viral suppression
among the displaced group (76% versus
58%, p=0.02) [27].
Our direct experience comes from
delivering and evaluating ART pro-
grams as part of UNHCR’s mandate to
protect refugees. We conducted two
evaluations using virologic outcomes in
two stable refugee settings (Table 1). In a
stable urban setting (Kuala Lumpur,
Malaysia), similar proportions of refu-
gees and host nationals accessing treat-
ment from a shared clinic achieved viral
suppression (83% overall), while propor-
tions adhering to treatment were similar
according to pharmacy refill records and
self-reports [28]. In a stable refugee
camp (Kakuma, Kenya), considerably
lower proportions (50% overall) of both
groups on treatment for$25 weeks were
virologically suppressed [29]. This dis-
crepancy may have been due to unver-
ified adherence lapses, background levels
of drug resistance, or high ambient
medication storage temperatures [29].
These evaluations, in combination with
evidence from other settings, suggest that
treatment outcomes among stable refu-
gees or IDPs, and host nationals, are
similar when treatment and support is
accessed from a shared clinic. Therefore,
similar levels of viral suppression should
be expected, although more challenging
settings will require more intensive and
specialized support for all population
groups. Even in stable settings, disrup-
tions may still occur. During the 2008
post-election violence in Kenya, an
otherwise stable setting, people on ART
appeared to have difficulties locating
and/or taking their treatment. During
this period of instability, 16% of clients
on ART interrupted their treatment, as
compared with 10% during a stable
comparison period, and mortality rates
increased [30,31]. In stable settings at
increased risk for disruption, the poten-
tial negative effects of treatment inter-
ruptions may be lessened if the period of
disruption is short, there are strong
contingency plans in place for ensuring
continuing access to treatment, and
people on ART have been educated on
how to best manage their treatment in
these challenging circumstances.
Recommendations
Despite the challenges, there is now general
agreement on the public health, human-
itarian, and human rights arguments that
support access to ART for refugees and IDPs
when clinically indicated [32–35]. To this
end, donors, health care workers, and hosting
countries should collaborate on strategies for
expanding access and providing the necessary
supportive services. On the basis of our
experiences implementingART interventions
for refugees and IDPs in stable post-conflict
settings, our own rigorous evaluations of two
such programs, and the experiences of others
in this area, we have proposed a set of
operational recommendations in support of
ART programs for refugees and IDPs
situated in stable settings (Table 2). These
recommendations are intended to comple-
mentWHO’s new consolidated guidelines on
the use of antiretroviral drugs [36].
Table 1. Results of UNHCR-sponsored evaluations conducted in Malaysia and Kenya.
Outcome Malaysia Kenya
Refugee Host National p-Value Refugee Host National p-Value
Viral suppressiona 81% (98/121) 84% (105/125) 0.54 58% (34/59) 43% (31/72) 0.10
$95% pharmacy refillb (24 months) 74% (101/136) 66% (95/143) 0.15 85% (62/73) 74% (64/86) 0.09
$95% self-reported adherenceb (past month) 72% (110/153) 70% (104/148) 0.79 62% (45/73) 28% (24/86) 0.002
a$25 weeks on treatment; cut-offs: Malaysia, 40 copies/ml and Kenya, 5,000 copies/ml. The difference in cut-offs was due to collection method: blood plasma was
collected using routine phlebotomy services in Malaysia and whole blood was collected as dried blood spots in Kenya. Note that the 5000 copies/ml cut-off used here
differs from the 1000 copies/ml reported previously [29]. A higher cut-off has been used to conform to current guidelines [36].
b$30 days on treatment.
doi:10.1371/journal.pmed.1001643.t001
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Table 2. Recommendations for provision of antiretroviral therapy to refugees and IDPs in stable settings.
Theme Recommendation Stakeholder(s)
Initiation and
distribution of ART
1. Start or continue treatment as soon as it is clinically indicated. Scale-up HIV counseling and testing to
facilitate treatment initiation according to national guidelines. Ensure equitable access to treatment
and testing for refugees and IDPs, and key populations among them (e.g., gay men, men who have sex
with men, people who inject drugs, transgender persons, and sex workers). Absence of routine
laboratory monitoring should not be used as a reason to deny treatment [55].
Health care providers; MOH;
donors
2. Distribute ART through partnerships with decentralized pharmacy networks to reduce travel
burden. Where multi-tablet regimens are indicated, facilitate refills of full prescriptions at one
pharmacy location.
3. Deliver medication directly to clients who are disabled, or who do not regularly attend the
clinic because of stigma, disability, or prohibitive cost.
4. Disburse medications with clear and validated pictorial dosing instructions that may be
understood by individuals from different linguistic and educational backgrounds.
5. Carefully manage medication storage conditions to ensure that appropriate temperatures are
maintained. Decentralize storage facilities where there is a risk of local insecurity (e.g., conflict, theft).
Adherence support
and monitoring
6. Support point-of-care patient laboratory monitoring for both pre-ART and ART clients. Use
viral load testing to diagnose or confirm treatment failures [36].
7. Update clinical guidance for treatment continuation given length of possible treatment
interruption and client treatment history.
8. Adopt a routine adherence monitoring system using a counselor-administered or
self-administered visual analogue instrument and pharmacy refill measures. The system should
be rights-based (e.g., voluntary consent required for participation). Integrate medical and pharmacy
records to facilitate identification of missed prescription refills. If multiple pharmacies are
accessed by individual clients, link the pharmacy records to facilitate accurate monitoring of
adherence to refill schedules.
9. Train, support, and evaluate community health and counseling teams. Sensitize counselors to local
gender, ethnic, and linguistic challenges. Work in teams to ensure continuity of counseling in
the event of sudden leave or dislocation. Avoid parallel programs.
Health care providers;
pharmacies; MOH; donors
10. Develop a basic package of locally appropriate adherence interventions, and a more
intensive package for groups at high risk of adherence lapses, focusing on those who live far from
clinics. Pilot-test counseling, mobile phone SMS, and peer-support interventions to improve
adherence. Peer-support groups for both clients and health care providers can facilitate
troubleshooting of local challenges.
11. Provide training to ART clients in identification of non-reputable treatments
and best practices for managing treatment interruptions. Provide an emergency toll-free hotline for
clients and treatment providers. Provide clients with a travel kit that contains: (i) a ‘‘Health Passport’’
that details ART history and laboratory tests; (ii) a regional clinic roadmap with details of alternative
local and cross-border clinics where ART is available; (iii) a transfer-out or referral letter; (iv) a three
month buffer supply of the current ART regimen; (v) a dual nucleoside regimen for ‘‘covering the
tail’’ of non-nucleoside reverse transcriptase inhibitor based regimens in case of treatment
interruption; (vi) a tracking form with a self-addressed, stamped envelope to be submitted upon
returning to the ‘‘home’’ clinic or to be posted to the home clinic upon enrolment in a new program
[56]. Set up referral systems for those who are repatriated, resettled, or returning home within the
same country.
Law enforcement 12. Provide interventions within law enforcement institutions of the rights accorded to refugees,
IDPs, and asylum-seekers.
MOH; law enforcement agencies;
United Nations agencies
Health systems 13. Plan for changes in treatment guidelines that may affect ART supply chains. Allow a transitional
overlap between the discontinuation of an old regimen and the implementation of a
new regimen. Avoid situations where stock-outs or the threat of stock-outs encourage forced
alteration of refill schedules.
MOH; health care providers;
pharmacies; donors
14. Include diagnosis and treatment of tuberculosis as an integrated one-stop service along with HIV
services, with particular attention to infection control.
Funding 15. Distinguish between different conflict-affected persons and forcibly displaced groups in all
proposals to major donors, indicating specific activities for each group. Formalize responsibilities and
identify key stakeholders within national governments, non-governmental organizations, and United
Nations agencies.
MOH; United Nations agencies
16. Develop regional initiatives to fund linkages between clinics and pharmacies. Share national and
international resources so refugees/IDPs and local host communities may collectively benefit from
interventions.
Research 17. Build on the evidence-base with prospective cohorts, intervention studies, studies among
children and young people, studies among key populations, and studies of drug-resistance.
ART, antiretroviral therapy; MOH, Ministry of Health; NSP, National Strategic Plan; PEPFAR.
doi:10.1371/journal.pmed.1001643.t002
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First, treatment should be offered to all
refugees and IDPs who meet national
guidelines (Recommendation 1). Despite the
known effectiveness of ART, some govern-
ments may be reluctant to provide it to these
groups owing to a misplaced belief that
starting or continuing them on treatment
may make it difficult for them to return home
and that ART may serve as a pull factor,
drawing additional refugee claimants to the
country. However, the majority of hosting
countries (88%) provide equitable access to
ART for refugees and IDPs, UNHCR has
not noted such a pull factor [37], and
international humanitarian law entitles refu-
gees to equitable access. IDPs should clearly
benefit from inclusion in their national HIV
programs. Scaling-up of HIV counseling and
testing so all who are eligible are given a
chance to initiate ART at the optimal time
will save lives and reduce costs by increasing
survival and reducing HIV transmission
[2,3,38]. Appropriate measures must be
taken to ensure that key populations (e.g.,
men who have sex with men, people who
inject drugs, transgender persons, and sex
workers) within refugee, IDP, and host
national groups also receive equitable access
to treatment and testing.
ART should be available in convenient
locations through decentralized networks of
clinics and pharmacies (Recommendation 2)
or delivered directly to clients who are unable
to access the medications themselves (Rec-
ommendation 3). Dosing instructions that are
designed and proven to be universally
understood should be provided with each
medication refill (Recommendation 4). In
areas with extreme ambient temperatures,
drug stocks should be stored carefully and
within the temperature ranges suggested by
manufacturers (Recommendation 5).
Adherence monitoring and support is
crucial for achieving consistent treatment
outcomes and can help to avoid costly
treatment failures. Viral load testing should
be used to diagnose or confirm treatment
failures (Recommendation 6) and may be
done on an annual basis or as often as
resources will permit. Pharmacy-based and
self-reported measures should also be used to
routinely monitor adherence (Recommenda-
tion 8). Although adherence self-reports may
overestimate adherence, they have diagnos-
tic value, are easy to implement in clinical
settings, and can help to complement
pharmacy refill measures when the period
between refills is lengthy or if the pharmacy
data is inconsistently recorded. Both mea-
sures are consistent with previous recom-
mendations and are associated with virologic
outcomes [39–41].
Community health and counseling teams
who are sensitized to gender, ethnic, and
linguistic challenges should be mobilized
(Recommendation 9). Interventions that
employ mobile phone text messaging, en-
hanced counseling and peer-support should
be pilot-tested among refugees and IDPs to
assess acceptability and effectiveness [42–44].
Addressing travel distances to clinics and
transportation costs are crucial as longer
travel times and higher costs may increase the
likelihood of treatment interruptions [45–47].
Peer-support groups for both clients and
health care providers can facilitate trouble-
shooting of local challenges (Recommenda-
tion 10). Refugees and IDPs may travel to re-
unite with family in host countries, repatriate
to their home country, or resettle to a new
country. Even in stable settings, proper
preparations for the possibility of onward
displacement are important to include in
programming and will serve the dual purpose
of preparing people on treatment for sudden,
unexpected instability (Recommendation 11).
[48] As barriers to accessing treatment and
supportive services sometimes include fear of
detention by law enforcement officials during
routine transit in urban and rural settings,
interventions are needed to increase aware-
ness among law enforcement officials of the
rights accorded to refugees, asylum-seekers,
and IDPs (Recommendation 12) [49].
As treatment guidelines change, new
regimens will need to be stocked and
distributed. Measures should be taken to
avoid situations where stock-outs or the threat
of stock-outs lead to forced alteration of ART
refill schedules. Remote pharmacies and
clinics (e.g., refugee camps) are advised to
allow a transitional overlap of between the
discontinuation of an old regimen and the
implementation of a new regimen (Recom-
mendation 13). There is a lack of integration,
in general, between HIV and other programs
including TB services; clinical settings serving
refugees and IDPs are no different [50].
Diagnosis and treatment of tuberculosis
should therefore be integrated with HIV
services (Recommendation 14).
Host countries are advised to include
specific results-oriented interventions for
refugees and IDPs in their NSPs, Global
Fund, and PEPFAR proposals (Recommen-
dation 15). These proposals should identify a
plan for equitable access to ART and which
agencies will be responsible for program
delivery [51]. Regional initiatives can facili-
tate partnerships in treatment management
by providing a framework for assisting those
who move within a country or across an
international border, while helping to mon-
itor and distinguish clients who are success-
fully re-integrated into treatment programs
elsewhere from those who have been lost to
follow-up. By engaging in partnerships with
humanitarian organizations, governments
can leverage international funds for the
benefit of their own citizens as well as the
groups they are hosting (Recommendation
16) [52]. Finally, there is a continuing need
for additional evidence. As the majority of
research has been conducted among adult
refugees and IDPs, there is a need for
research among children and young people
[53,54]. As past studies among refugees and
IDPs have largely focused on short-term
outcomes, prospective cohort studies or
intervention studies with virologic endpoints
are needed. We are not aware of any data on
rates of acquired or transmitted drug resis-
tance among these groups (Recommendation
17).
Overall, this set of recommendations will
face a range of implementation barriers
including resource constraints and coordina-
tion challenges among stakeholders. Howev-
er, these improvements will be necessary if
sustainable treatment outcomes are to be
achieved among refugees and IDPs who live
in stable settings.
Conclusions
Given recent evidence and the moral,
legal, and public health arguments, refugees
and IDPs situated in stable settings should
have equitable access to HIV treatment and
supportive services. Despite encouraging
treatment outcomes among these groups
across a range of settings, considerable
challenges persist. Programs that are not
achieving high levels of success should serve
as a call for intervention, not exclusion. Few
would rationally argue that challenges to
providing life-saving treatment should be
addressed by denying access. Since antiret-
roviral therapy can help prevent onward
transmission of HIV to sexual partners [2], it
is in the enlightened self-interest of govern-
ments that host refugees and IDPs to support
programs that serve all populations within
their borders to the highest possible stan-
dard.
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